Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment.
Fiche publication
Date publication
novembre 2022
Journal
Cells
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr REBE Cédric
Tous les auteurs :
Roussot N, Ghiringhelli F, Rébé C
Lien Pubmed
Résumé
The success of anticancer treatments relies on a long-term response which can be mediated by the immune system. Thus, the concept of immunogenic cell death (ICD) describes the capacity of dying cancer cells, under chemotherapy or physical stress, to express or release danger-associated molecular patterns (DAMPs). These DAMPs are essential to activate dendritic cells (DCs) and to stimulate an antigen presentation to CD8 cytotoxic cells. Then, activated CD8 T cells exert their antitumor effects through cytotoxic molecules, an effect which is transitory due to the establishment of a feedback loop leading to T-cell exhaustion. This phenomenon can be reversed using immune checkpoint blockers (ICBs), such as anti-PD-1, PD-L1 or CTLA-4 Abs. However, the blockade of these checkpoints is efficient only if the CD8 T cells are recruited within the tumor. The CD8 T-cell chemoattraction is mediated by chemokines. Hence, an important question is whether the ICD can not only influence the DC activation and resulting CD8 T-cell activation but can also favor the chemokine production at the tumor site, thus triggering their recruitment. This is the aim of this review, in which we will decipher the role of some chemokines (and their specific receptors), shown to be released during ICD, on the CD8 T-cell recruitment and antitumor response. We will also analyze the clinical applications of these chemokines as predictive or prognostic markers or as new targets which should be used to improve patients' response.
Mots clés
CD8, chemokines, immune checkpoint blockers, immunogenic cell death
Référence
Cells. 2022 11 18;11(22):